Aeglea BioTherapeutics, Inc. (AGLE)
(Delayed Data from NSDQ)
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
New Analyst Coverage Puts Spotlight on These 2 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Aeglea BioTherapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics
Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Is Aeglea BioTherapeutics (AGLE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGLE) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources
by Zacks Equity Research
Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources
4 Stocks in the Limelight on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Find Strong Stocks During the Coronavirus with New Analyst Coverage
by Benjamin Rains
Today we screened for strong stocks that recently received new analyst coverage...
Is Aeglea BioTherapeutics (AGLE) Stock a Solid Choice Right Now?
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Aeglea BioTherapeutics, Inc. (AGLE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).
Aeglea (AGLE) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aeglea (AGLE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
by Zacks Equity Research
Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
by Zacks Equity Research
Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
by Zacks Equity Research
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
Roche's Breast Cancer Study Meets Co-Primary Endpoint
by Zacks Equity Research
Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
Celgene's Luspatercept Meets Primary Endpoint in the Study
by Zacks Equity Research
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announces top-line results from a phase III, multi-center study (MEDALIST), where its pipeline candidate luspatercept met both the primary and secondary endpoints.
4 Biotech Stocks to Bet on in the Second Half of 2018
by Ekta Bagri
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Medicines Company's Inclisiran Studies to Continue Unmodified
by Zacks Equity Research
The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.
Infinity and Arcus Ink Deal for Two Triple Combo Studies
by Zacks Equity Research
: Infinity Pharmaceuticals, Inc. (INFI) and Arcus Biosciences, Inc. (RCUS) sign a deal to evaluate two triple combination therapies in selected tumor types.
Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote
by Zacks Equity Research
Puma Biotechnology's (PBYI) marketing application seeking approval for neratinib in breast cancer gets positive CHMP trend vote, following a negative opinion in February.
Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies
by Zacks Equity Research
Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.
Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
by Zacks Equity Research
Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.
Merrimack Crashes as Phase II Pancreatic Cancer Study Fails
by Zacks Equity Research
Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.